The DEPICT-2 Study demonstrated that dapagliflozin at 5 mg or 10 mg add-on insulin therapy was safe and well tolerated and exhibited a potential benefit in improving glycemic control and hypoglycemia in T1D [32]. The gene discussed is INS; the disease is Hypoglycemia.